Drug Trial Radar · NCT07251062
A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.
Last checked: Nov 19, 2026Latest source record: Nov 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
737
Planned (sponsor's estimate)
Start
Dec 30, 2025
Primary completion
Dec 30, 2029
Study completion Dec 30, 2030
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter phase 2/3 clinical study to evaluate the efficacy and safety of SYS6010 plus SG001±5-FU/Capecitabine as first-line treatment, in patients with advanced/metastatic esophageal squamous cell carcinoma.
Conditions
- Esophageal Squamous Cell Carcinoma
Interventions
SYS6010+SG001+ physician's choice (Capecitabine or 5-FU)Drug
SYS6010 is an antibody conjugate drug (ADC), composed of one anti-EGFR monoclonal antibody coupled to one JS1 via an enzyme specific linker. SG001 is a recombinant, fully human, anti-PD-1 monoclonal antibody. Capecitabine: Capecitabine is for oral administration. 5-FU: Administration at the conventional dosage.
Investigator's choice of SOCDrug
1. Camrelizumab + Cisplatin + Paclitaxel 2. Tislelizumab + Cisplatin + Paclitaxel 3. Tislelizumab + Cisplatin + 5-FU/Capecitabine
SYS6010+SG001Drug
SYS6010 is an antibody conjugate drug (ADC), composed of one anti-EGFR monoclonal antibody coupled to one JS1 via an enzyme specific linker. SG001 is a recombinant, fully human, anti-PD-1 monoclonal antibody.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PhaseII(safety leadrun-in stage): DLT; Description: Dose-limiting toxicityTime frame: 28 days
- PhaseII(safety run-inlead-in stage): AETime frame: From the signing of the informed consent form until 90 days after the last dose.
- PhaseII(safety leadrun-in stage): MTD;Time frame: After phase II saftysafety run-inlead-in stage and dose expansion stage. Approximately 4 months.
- PhaseII(safety run-inlead-in stage): RP2DTime frame: After phase II saftysafety run-inlead-in stage and dose expansion stage. Approximately 4 months.
- PhaseII(Randomized treatment stage): ORR per RECIST v1.1Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.
- PhaseIII: PFS-ICRTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years
- PhaseIII: OS;Time frame: Through study completion, up to approximately 5 year.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.